Comparison of fludarabine-containing salvage chemotherapy regimens for relapsed/refractory acute myelogenous leukemia [8]

Leukemia

Volumn 17, Issue 5, 2003, Pages 990-993

  Thomas, M B ^a   Koller, C ^c   Yang, Y ^b   Shen, Y ^b   O'Brien, S ^c   Kantarjian, H ^c   Davis, J ^c   Estey, E ^c  

^a Division of Cancer Medicine   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYTARABINE; CYTARABINE TRIPHOSPHATE; DAUNORUBICIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; IDARUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; BLAST CELL; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG POTENTIATION; HUMAN; LETTER; LEUKEMIA REMISSION; PRIORITY JOURNAL; RELAPSE; SALVAGE THERAPY; STATISTICAL ANALYSIS; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0037851050     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402862     Document Type: Letter

References (8)

1. Estey E, Plunkett W, Gandhi V, Rios MB, Kantarjian H, Keating MJ. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leukemia Lymphoma 1993; 9(4-5): 343-350.
2. Marlton P, Keating M, Kantarjian H, Pierce S, O'Brien S, Freireich EJ et al. Cytogenetic and clinical correlates in AML patients with abnormalities of chromosome 16. Leukemia 1995; 9(6): 965-971.
3. Visani G, Tosi P, Zinzani PL, Manfroi S, Zaccaria A, Testoni N et al. FLAG (fludarabine+cytosine arabinoside+G-CSF) induces complete remission in acute-phase chronic myeloid leukaemia: a case report. Br J Haematol 1994; 86(2): 394-396.
4. Montillo M, Mirto S, Petti MC, Latagliata R, Magrin S, Pinto A et al. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia. Am J Hematol 1998; 58(2): 105-109.
5. Parker JE, Pagliuca A, Mijovic A, Cullis JO, Czepulkowski B, Rassam SM et al. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol 1997; 99(4): 939-944.
6. Estey E, Thall P, Andreeff M, Beran M, Kantarjian H, O'Brien S et al. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 1994; 12(4): 671-678.
7. Heinemann V, Estey E, Keating MJ, Plunkett W. Patient-specific dose rate for continuous infusion high-dose cytarabine in relapsed acute myelogenous leukemia. J Clin Oncol 1989; 7(5): 622-628.
8. Seymour JF, Huang P, Plunkett W, Gandhi V. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule. Clin Cancer Res 1996; 2(4): 653-658.